Globus Medical (NYSE:GMED) Cut to Hold at Wall Street Zen

Posted by George Bondi on Nov 10th, 2026

Wall Street Zen downgraded shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other equities analysts also recently weighed in on the stock. Canaccord Genuity Group reduced their target price on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday. Needham & Company LLC dropped their price target on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Truist Financial cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $96.08.

Read Our Latest Stock Report on Globus Medical

Globus Medical Stock Performance

GMED stock opened at $76.60 on Friday. The stock has a fifty day moving average of $77.07 and a 200-day moving average of $83.09. Globus Medical has a fifty-two week low of $70.39 and a fifty-two week high of $101.40. The company has a market capitalization of $10.28 billion, a price-to-earnings ratio of 17.70, a PEG ratio of 1.40 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts predict that Globus Medical will post 4.99 EPS for the current year.

Insiders Place Their Bets

In other news, Director Ann D. Rhoads sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the sale, the director directly owned 35,384 shares in the company, valued at $3,007,640. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director James Tobin sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,000 shares of company stock worth $4,838,400 in the last quarter. 18.38% of the stock is owned by company insiders.

Hedge Funds Weigh In On Globus Medical

A number of large investors have recently modified their holdings of GMED. Paradigm Capital Management Inc. NY purchased a new position in Globus Medical during the second quarter valued at approximately $70,042,000. American Capital Management Inc. purchased a new stake in Globus Medical in the 2nd quarter worth approximately $51,599,000. Hawk Ridge Capital Management LP purchased a new stake in Globus Medical in the 1st quarter worth approximately $43,078,000. Arrowstreet Capital Limited Partnership lifted its stake in Globus Medical by 107.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.